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Background and Objectives: In the head and neck region, value, reliability, and
safety of sentinel lymph node biopsy (SLNB) have not yet been determined
conclusively. The aim of study was to assess impact of SLNB on disease outcome in
cutaneous head and neck melanoma.
Methods: Thirty-six patients with a clinically node-negative head and neck
melanoma, 1.0 mm Breslow thickness, participated in a prospective study from
1995 to 2005. Sentinel lymph node (SLN) tumor-positive patients underwent
completion lymphadenectomy. SLN tumor-negative patients underwent clinical
monitoring. Median follow-up was 54 (range 10–114) months. Recurrence-free and
overall survival curves were constructed by Kaplan–Meier.
Results: SLNs could be identified in 33 patients (92%). In 7 patients (21%) the SLN
was tumor-positive. In 1 patient (13%) the SLNB was false-negative. In 17 patients
(47%) SLNs could be identified in the parotid region (success rate parotid region
100%). This study showed no significant difference in recurrence-free and overall
survival between patients with tumor-positive and tumor-negative SLN.
Conclusions: The safety and accuracy of SLNB in the neck and parotid nodal basins
were similar to those in non-head and neck sites. However, the technique is technically
demanding in this region. In this small series SLNB did not alter disease outcome.
J. Surg. Oncol. 2006;93:564–570.  2006 Wiley-Liss, Inc.
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INTRODUCTION
The incidence of cutaneous melanoma in the head and
neck region has increased in recent years, along with an
overall increase in the incidence of cutaneous melanoma
world-wide. The key to survival is early detection of this
malignancy and indeed melanoma is currently diagnosed
in an earlier stage with thinner melanoma [1]. Early
detection and treatment of micrometastatic disease might
further improve recurrence-free, and overall survival.
Primary cutaneous melanomas in the head and neck
region are considered to be more aggressive than
melanomas on the arms and legs [2]. Therefore, debate
continues about the best management for clinically
negative cervical lymph nodes. Prospective studies,
performed in the past did not proof any benefit of
elective lymphatic dissection for these patients [3–5]. A
combination of high relapse rates and the persisting lack
of effective treatment for recurrent disease has focused
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attention on optimizing initial management as a means of
improving the overall outcome. The value and reliability
of SLNB as a staging procedure in melanoma have been
well-described in the literature since it was first reported
in 1990, but final results of the multicenter selective
lymphadenectomy trial (MSLT I) are still pending [6,7].
SLNB can identify indeed patients who may theoretically
benefit from complete lymph node dissection. Melano-
mas located on the head and neck have an extremely
unpredictable drainage pattern [8,9]. SLNB in the head
and neck region presents unique challenges in terms of
anatomy and surgical technique. The value, safety,
reliability, recurrence-free and overall survival rates of
SLNB in patients with cutaneous melanoma in the head
and neck region were evaluated and discussed with
respect to the current literature.
MATERIALS AND METHODS
Patients
From May 1995 to 2005, 36 patients (15 females
(42%) and 21 males (58%)), median age 58 years (range
25–79 years) with a cutaneous melanoma 1.0 mm
Breslow thickness in the head and neck region were
enrolled in a prospective registration study at the Division
of Surgical Oncology of the Groningen University
Medical Center. Informed consent was obtained from
all patients. The primary melanomas were diagnosed by
excisional biopsy. None of these patients had undergone
excision of the primary tumor with margins of >1.5 cm.
Patients with palpable regional lymph nodes and/or
clinical evidence of distant metastases, pregnant women
and children and adolescents (<18 years) were excluded
from this study.
Lymphoscintigraphy
A 2-day protocol on an inpatient basis was used.
Lymphoscintigraphy was performed on the day preceding
the operation. A single dose of unfiltered 40–60 MBq
99mTc nanocolloid (Nanocoll1; Amersham Cygne,
Eindhoven, the Netherlands) with a particle size of
<80 nm in 0.2 ml of saline was injected intradermally
around the primary tumor site at two to four locations.
Injection sites were covered with lead shielding.
Dynamic imaging in the supine position with a low
energy high resolution collimator to visualize lymph flow
was commenced immediately after tracer administration
and continued for 20 min at a frame rate of 30 sec/image.
Subsequently, static supine and lateral views were
obtained. A radioactive flood source was used to outline
the body contour. Another set of static images was taken
2 hr later. All possible lymph drainage regions were
imaged. The position of the SLN(s) was marked on the
skin with indelible ink. The images were discussed by an
interdisciplinary team comprising the nuclear medicine
physician and the surgical oncologist prior to the
operation.
Surgery
After the induction of general anesthesia, but 15–
20 min before surgery, an injection of 0.3–1.0 ml Patent
Blue V (Bleu Patente´ V1, Laboratoire Guerbet, Aulnay-
sous-Bois, France) was administered intradermally
around the melanoma scar. All nodal basins identified
by lymphoscintigraphy were explored surgically through
limited incisions. Surgical dissection was guided by a
hand-held g-detection probe (Neoprobe11000 and 1500,
Johnson & Johnson Medical BV) and by looking for blue-
stained afferent lymphatic vessels that led to blue-stained
SLNs. Once the SLNs had been excised the probe was
used to search the resection bed to ensure that there were
no residual areas of high radioactivity. If necessary,
additional hot nodes were removed until the ratio of the
hottest ex vivo SLN to the residual basin was >10:1 [10].
After SLNB, wide local excision of the primary
melanoma scar was performed with 1 or 2 cm margin
depending on the tumor thickness (Breslow) and the
anatomical location of the melanoma. If pathological
examination was positive for tumor cells on hematoxylin-
eosin (HE) or immunohistochemical (IHC) staining,
cervical or posterior lymph node dissection was
performed with the standard surgical procedure. If SLNs
were negative for tumor cells on pathological examina-
tion, the lymph node basins were monitored clinically
during follow-up.
Pathology
After marking the hottest part of the SLN with a stitch,
each harvested SLN was sent for pathological examina-
tion. Owing to low sensitivity (38%) of frozen section
analysis with HE in the first 11 patients, we subsequently
delayed SLN evaluation in order to perform permanent
sectioning.
The SLNs were fixed in 10% neutral buffered formalin
and blocked in paraffin. Serial 4 mm thick sections of all
paraffin-embedded material were evaluated with routine
HE and IHC staining for S100 protein and melanoma-
associated antigen HMB45. This procedure was repeated
at levels of 500 mm until all the tissue was sectioned
(average: 9 levels). Two paraffin-embedded cross-sec-
tions of each lymph node were stained with HE without
any additional IHC.
Follow-Up
Patients were seen for physical examination every 3,
4, 6, and 12 months in the 1st, 2nd, 3rd–5th and
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5th–10th years, respectively. A chest X-ray was taken
once a year. In patients who developed tumor recurrence
in the same nodal basin, recurrence patterns were
analyzed. All previously identified tumor-negative SLNs
were re-evaluated on original slides and IHC-stained
additional deeper sections of the SLNs. Duration of
follow-up was calculated in months from the date of
SLNB to the date of last follow-up or death. None of the
patients were lost to follow-up. Median follow-up was
54 (range 10–114) months.
Statistical Analysis
Recurrence-free and overall survival curves were
constructed for SLN-positive and SLN-negative patients
using the Kaplan–Meier method and compared using
the log-rank procedure. Significance was defined as
P< 0.05. Results are presented as median (range) and as
percentages when appropriate.
RESULTS
Fifteen females (42%) and 21 males (58%) with a
median age of 58 (range 25–79) years with a cutaneous
melanoma,1.0 mm Breslow thickness (median 2.5 mm,
range 1.0–8.1) were included (Table I). At least one SLN
was identified in 33 (92%) out of the 36 patients. Wide
local resection with 1–2 cm margin had to be performed
before SLNB in 10 patients (28%), to reduce the high
background counts that interfered with SLN localization
by the g-detection probe.
A total of 97 SLNs were excised (median 2.9 nodes per
patient; range 1–7). These 97 SLNs were removed from a
total of 48 nodal basins (median 1.5 basin per patient;
range 1–3). In 23 patients (70%) the blue tracer was seen
together with the radioactive tracer intraoperatively. In
10 patients (30%) the SLNs were identified by the
radioactive tracer alone.
In two patients, SLNs were identified in an unexpected
node field, that is, the supraclavicular basin. In one of
them with a primary lesion on the earlobe, dynamic
lymphoscintigraphy showed direct drainage to both
the parotid region and the supraclavicular region. In the
other patient, direct drainage was seen from the pre-
auricular melanoma scar site to the subdigastric and
supraclavicular regions. In both patients, histopathology
of the SLNs in the unexpected and expected basins was
tumor-negative.
In 17 patients (47%), lymphoscintigraphy showed a
SLN in the parotid region. All SLNs could be identified in
this region (success rate 100%). In 12 patients (71%), the
parotid SLNs were tumor-free. In five patients (29%) the
parotid SLNs were tumor-positive. These patients under-
went subtotal parotidectomy with modified neck dissec-
tion. No additional tumor-positive lymph nodes were
found on histopathological examination. After exploration
of the parotid gland or after re-operation that comprised
subtotal parotidectomy no complications occurred.
In total, a tumor-positive SLN was diagnosed in seven
patients (tumor-positive SLN-rate 21%).
So far, 12 patients (33%) have developed recurrence
of the disease. The distribution of the first site of the
metastases was as follows: 4 (11%) with in-transit
recurrence; 2 (6%) with recurrence in the regional lymph
node basin; and 6 (17%) with a distant recurrence. The
distribution of the first site of the metastases according to
tumor status of the SLN is shown in Table II. The SLNB
result was false-negative in one of seven positive SLNB
results (false-negative rate 13%).
Recurrence-free and overall survival were not signifi-
cantly associated with the results of the SLNB. The 5-year
recurrence-free survival in SLN-tumor-negative patients
and SLN-tumor-positive patients was 65% and 50%
respectively (P< 0.6133). The overall survival at 5 years
was 55% and 66% respectively (P< 0.5951) (Figs. 1 and 2).
The overall morbidity related to this procedure was
minimal. No anaphylactic reactions occurred following
the injection of radioactive tracer or Patent Blue V. All
the patients had normal postoperative cranial nerve
function, including the facial nerve.
DISCUSSION
Sentinel lymph node biopsy in head and neck
melanoma is a challenge for the surgeon. In this series
Journal of Surgical Oncology DOI 10.1002/jso
TABLE I. Clinical and Pathological Characteristics of 36 Patients
With a Cutaneous Melanoma in the Head and Neck Region


















Superficial spreading 11 30
Nodular 17 47
Lentigo maligna 2 6
Unclassified 1 3
Other 5 14
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SLNB succeeded in 33 of the 36 patients (success rate
92%). This is in contrast to our series of 266 non-head
and neck melanoma patients in which we could identify
all SLNs (success rate 100%) [11].
Various features may have contributed to the failures:
(1) primary tumor site overlying the draining basin(s), (2)
learning curve of the surgeon, (3) high radioactivity
level (40–60 MBq), (4) lymphoscintigraphy collimator
problems, artefacts, (5) volume of tracer too large, (6)
spillover into second echelon nodes, and (7) incorrect
injection technique, that is, if injection is not intradermal,
the lymphatic drainage may not be adequately demon-
strated.
The success rate of SLNB in the parotid region
was 100%. After SLNB in the parotid region, no
complications were observed. Our experience supports
the findings of others that SLNB of intraparotid nodes can
be performed safely by experienced surgical oncologists
specialized in surgical oncology procedures in the head
and neck area without formal parotidectomy [12,13]. The
procedure was performed with equivalent safety in the
neck and parotid nodal basins. In our opinion, when it has
been decided to do a SLNB, surgical oncologists should
not be reluctant to perform subtotal parotidectomy and/or
posterolateral neck dissection if the SLNB result is
tumor-positive.
Is our false-negative rate of 13% high? Table III
illustrates the great variation in the false-negative rates
for SLNBs in head and neck melanoma as published in
the literature [14–31]. In determining the rate of false-
negative results, a mistake that is sometimes made is to
calculate the rate over the entire group of patients, both
those who are tumor-positive and those who are tumor-
negative. The outcome is too flattering with this
Journal of Surgical Oncology DOI 10.1002/jso
Fig. 1. Recurrence-free survival plot according to Kaplan–Meier.
SLN, sentinel lymph node tumor-negative; SLNþ, sentinel lymph
node tumor-positive.








Median follow-up, months 54 (range, 10–114) 49 (range, 10–99) 54 (range, 13–88)
Recurrence, No (%) 12 (33) 8 (31) 3 (43)
Median time to recurrence, months 43 (range, 3–110) 40 (range, 3–87) 38 (range, 6–85)
Site of first recurrence, No (%)
In-transit 4 (11) 2 (8) 2 (29)
Nodal 2 (6) 1 (4) 0
Systemic 6 (17) 5 (19) 1 (14)
SLN, sentinel lymph node tumor-negative; SLNþ, sentinel lymph node tumor-positive.
Fig. 2. Overall survival plot according to Kaplan–Meier. SLN,
sentinel lymph node tumor-negative; SLNþ, sentinel lymph node
tumor-positive.
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TABLE III. Results of SLNB in Head and Neck Melanomas Obtained by Various Investigators
Author Year of publication Number of patients SLN identified (%) False-negative (%)b
Morton [14] 1993 72a 90 0
O’Brien [15] 1995 20 75 50
Wells [16] 1997 58 95 0
Bostick [17] 1997 117a 93 0
Alex [18] 1998 23 96 0
Wagner [19] 2000 70a 99 12
Jansen [20] 2000 30 90 20
Carlson [21] 2000 57 96 0
Medina-Franco [22] 2001 38 92 20
Eicher [23] 2002 43 98 0
Patel [24] 2002 56 96 20
Schmalbach [25] 2003 80 96 18
Chao [26] 2003 321 97 12
De Wilt [27] 2004 362 99 44
Fincher [28] 2004 51 100 0
Shpitzer [29] 2004 30 93 20
Lin [30] 2005 80 99 24
Carlson [31] 2005 132 95 29
Current study 2005 36 92 13
SLN, sentinel lymph node.
aIncluding trunk.
bThe percentage of false-negative procedures is calculated over the patients with tumor-positive SLNs.













N % N %
Gershenwald [35] 1998 Trunk and
extremities
1.60 243b 12a 5 — — 35
Gadd [36] 1999 Extremities
and axial
1.8 89b 2a 2.2 — — 23
Essner [37] 1999 All 1.9 267 6a 2.7 4a 9.5 45
Clary [38] 2001 All 2.1 303 14a 5.6 9a 16.1 23
Statius Muller [39] 2002 All 1.4 248 10a 5 13a 27 38
Estourgie [40] 2003 All 2.7 250 24a 12.6 17a 28.3 72
Vuylsteke [41] 2003 All 1.41 209 11 6.5 13 32.5 23
Wagner [42] 2003 All 2.27 408 13a 4.0 5a 5.9 31.4
Tiffet [43] 2004 All 3 132 3 2.7 2 9 27.1
Ariyan [44] 2004 All 1.7 263 2 1 3 11 32
Macripo [45] 2004 All 1.5 and 2.6c 274 8 3.5 2 4.3 34.8
Borgognoni [46] 2004 All ? 385 6 2.0 1 1.3 35
Gipponi [47] 2004 All ? 180 1 1.1 2 5.5 16.5
Yee [48] 2005 All 1.7 836b 10 1.2 — — 42.1
Van Poll [49] 2005 All 1.85 754 11 1.7 7 6.9 42
Pawlik [50] 2005 All 1.5 1,395 40 3.5 28 12.0 46.8
Current study This study Head and
neck
2.5 36 2 8 2 29 54
—, not mentioned.
FU, follow-up.
aLocal and in-transit recurrence.
bSLN-negative patients only.
cBreslow thickness in SLN- en SLNþ patients, respectively.
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approach. It is not possible to miss metastasis in a patient
who has no metastasis. The false-negative rate should be
calculated over the entire group of tumor-positive
patients, as follows:
False-negative rate
¼ no: of false-negative procedures
no: of false-negativeþ true-positive procedures 100%
The false-negative rates in Table III are adjusted
accordingly [32].
The number of patients with a positive SLN in our
study was small, which might have led to a high false-
negative rate on the basis of one false-negative result.
Reporting the false-negative rate for this procedure is
problematic, because it is difficult to make a reliable
assessment of the status of the remainder of the nodal
basin by using non-surgical means. The most accurate
approach would be to perform lymph node dissection
immediately after SLNB, so that the status of the
entire ‘‘at risk’’ nodal basin can be compared to that of
the SLN(s). An ideal solution would be to examine SLNs
and non-SLNs using immunohistochemical methods
and serial sectioning in equal detail to enable a truly
valid evaluation of the technique, but this is obviously
impractical. We used the current, generally more
acceptable method to determine false-negative rates:
documentation of the rate of nodal failure over time
within SLN-negative basins.
The performance of SLNB may in itself alter the
pattern of subsequent recurrence of melanoma, thus
increasing the incidence of in-transit recurrence [33,34].
In-transit recurrence is defined as that occurring between
the primary excision site and the regional node basin, but
excluding local recurrences within 3 cm of the primary
tumor site. In this small series we found two cases in
SLN-positive (2/7¼ 29%) and two cases in SLN-negative
(2/26¼ 8%) patients. Also other series are now publish-
ing high incidence rates in SLN-tumor-positive patients
(Table IV). However, our concern is not shared by others
like Coit [51], who stated that the overall incidence of in-
transit recurrence after SLNB is low and is most likely
influenced much more by patient, tumor, and lymph node
variables than by any treatment variable.
CONCLUSIONS
In the head and neck region, the multiplicity of lymph
nodes, their widespread distribution, small size, and their
proximity to vulnerable structures make the SLNB
procedure technically challenging. This study addressed
the value, safety, and reliability of SLNB to accurately
detect occult regional metastases in patients with
cutaneous melanoma in the head and neck region. During
a median follow-up of 4½ years, one patient developed an
isolated regional recurrence following a tumor-negative
SLNB. A sensitivity rate of 87% with minimal morbidity
indicates that SLNB is a reliable procedure for regional
staging of patients with cutaneous melanoma in the head
and neck region.
Recurrence-free and overall survival were not sig-
nificantly associated with the results of SLNB, but the
number of patients in this study was too small to draw any
definitive conclusions. The main question which is still
unanswered is whether SLNB will improve disease-free
and overall survival. Results of MSLT I are pending [7].
Although no consensus has been reached among
investigators as to whether SLNB followed by early
regional node dissection improves regional tumor control
(and patient survival), lymphatic mapping definitely
provides prognostic information [52]. If this is also true
for head and neck melanoma is questionable and is not
supported by this small study.
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